STL Biotech

@AIxGLP1 No but it is fair

@STL_Biotech Is it a positive write up?

Very good $CTMX

@TheBiotechBear 🔥

thank u LinkedIn translator, very cool!

Blossomhill Therapeutic will be presenting two new pan-KRAS (they called it next-gen) inhibitors utilizing a novel chemical scaffold. Doesn't sound like a me2 pan-KRAS Their BH-30643 4th Gen EGFR TKI showed some very interesting profiles previously as well The founding chemist Jean Cui had previously designed crizotinib, lorlatinib and repotrectinib. So an extremely talented chemist Looking forward to find out more about these new pan-KRAS inhibitors!

@BioStocks Yikes. Death knell

$BCYC existing Duravelo-2 trial design is no longer considered acceptable as an approval path for Zelenectide in mUC - program deprioritized for further development. Bicycle to convert the ongoing Duravelo-2 trial to a randomized Phase 2 study.

@Sanctuary_Bio @Banana_Oncology I would think multiples of that but dont have FDA guidance in front me. Most oncology AAs with n of ~100 or less have been biomarker/mutation specific and in small % subsets iirc.

@Banana_Oncology I doubt it. Data is good but n of 39 across 8.6 and 10 mpk? You probably need at least double that to qualify for a broad 3L+ AA

From the other half of my life (non-BioX), I was told that accelerated approval is feasible for oncology indication with high unmet need, if cORR is 30%+. Of course with the current FDA there's more uncertainty... But: 1) it's hard to deny late-line CRC is with extremely high unmet need 2) high dose $CTMX ADC has the potential to hit the 30%+ bar 3) VP who strongly opposed surrogate endpoints is now gone Thoughts?

$TYRA The amount of buzz/news flow on this name and the 6 month chart are surprisingly disconnected. Just keeps going

@anthonystaj I think you make a good point about colitis tho, budesonide is definitely Ppx-ing colitis not just diarrhea

$ctmx you know in myeloma when we give a steroid, dexamethasone, it's a letter in the regimen (dara-KR*d*) better start calling this varseta-b if you need to give budesonide. side effects can definitely add up over a few months

@anthonystaj Super low bioavailability, I've seen plenty of people on for months for IBD w/o typical systemic side effects.

$CTMX Almost all patients in highest dose saw shrinkage. 16 pts on Tx at data cut, longest 11 mos.

@MysteriousMole1 @semodough Double edged sword tho as ealier line stronger/healthier. Patients also seem younger and younger, often working, both an even bigger concern for diarrhea/QoL but also perhaps more willing to take more tox for better response, if ofc it would actually be competitive earlier-line

$CTMX Efficacy for 2 highest doses falls from 31% (n=13) to 26% (n=39). Which Beat most everyone bull case for this study - also would expect side effect profile to improve as it will move into earlier lines ???

@MysteriousMole1 @JacobPlieth Another thing to consider, higher ORRs and PFS *should* correlate with improved OS in a 4L trial vs rego or fruquitinib but it certainly doesn't always work out that way. Wont sleep well at night into that readout, given the tox and as you mention EpCAM heterogeneity.

My $CTMX expectations, from earlier this month

@anthonystaj I guess they are trying to separate pre/post mitigation strategy but ya i don't like it either.

Rlly don't like this slide tbh. Colitis and AKI where ? Also g3 diarrhea not really 10%

@JacobPlieth Pretty typical ORR decline for ph1 update and doubling N id say, and still above benchmarks, base-case?

$CTMX

Q now is late lane only vs earlier opportunity. Gr3 diarrhea, dehydration and colitis not nothing, esp as it will need combined. And how it will compare to CEACAM5 projects.

$CTMX Nice dose-response linearity. Data broken out by dose but even across all cohorts ORR would be 20%. All responses confirmed. No BS. They have a drug.

@BioYOLO420 Not quite even a 1% position, still gonna be up early refreshing lol

$ctmx last call?

@CloisterRes A+

Dave: Stephane from Boston, welcome to the show. SB: Good morning Dave, I run a public biotech company, and am just trying to make sure we have enough cash in the bank to avoid a going concern. Dave: That’s great, can you tell me how much cash you have? SB: Well, about six billion dollars at the end of the year. Dave: Rachel did you just hear that? SIX BILLION DOLLARS? Did you win the Massachusetts powerball or something? SB: Well, yeah, kind of. Dave: Wow. Wow. Well let’s see what we can do. You’re a public biotech company so you must have some SG&A expenses? SB: Yes sir. Dave: How much? SB: about 3 billion this year. Dave: 3 billion!? Are you kidding me? Buddy you are not Pfizer, you have got to start cooking your own meals at home instead of dining out! Ok what about R&D? SB: about a billion. Dave: you have GOT to be kidding me. Are you curing cancer or something? Ok what about COGS? SB: about a billion. Dave: So you are telling me that you have SIX BILLION DOLLARS and you’re going to burn five of them just running your business? SB: Well we have a lot of revenue. Dave: How much? SB: About two billion. Dave: Stephane, you realize how crazy this sounds? You’re selling two BILLION DOLLARS of product per year, but you’re burning more than double that in your cash costs of running the business. SB: yes sir. Dave: is there anything else? SB: Well we just settled a lawsuit for about two billion dollars. Dave: Rachel I can’t have heard that right. Another TWO BILLION DOLLARS. Ok, so you are burning in total about five billion dollars this year. And you have six billion dollars in the bank account. So what did you tell the street about how much cash you’ll end the year with? SB: Uh about five and a half. Dave: Dollars? That sounds about right. SB: No, I meant billions of dollars. Dave: Stephane we have to get serious here and confront reality. You are living a LIFESTYLE that your income cannot match! What was the name of your company? SB: It's called Moderna. Dave: That's great, thanks Stephane. Rachel, pull up my brokerage account. Rachel: I've got it Dave, what do you need. Dave: Can you tell me how much borrow there is? $MRNA

@BioWino Just saying WC called it after the STAT piece that VP was telegraphing his own exit.

@STL_Biotech @Sanctuary_Bio Wait whut? I remember a certain someone pounding table NOT to buy qure at 7 ish. Million takes and pump the best one?

I'm honestly surprised biotechs aren't rallying more. #1 risk right now imho is regulatory uncertainty. Why even bring up your past life in these conversations...unless...you know anyways think I'll go skiing on Monday

@TTRAmyloid Best case scenario

My prediction. Pazdur comes back